D'Haens GR - Search Results

1

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. Feagan BG, et al. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671-680. doi: 10.1016/S2468-1253(18)30233-4. Epub 2018 Jul 25. Lancet Gastroenterol Hepatol. 2018. PMID: 30056030 Free article. Clinical Trial.

2

Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.

D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. D'Haens G, et al. Gastroenterology. 1997 May;112(5):1475-81. doi: 10.1016/s0016-5085(97)70027-1. Gastroenterology. 1997. PMID: 9136824

3

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Baert FJ, et al. Gastroenterology. 1999 Jan;116(1):22-8. doi: 10.1016/s0016-5085(99)70224-6. Gastroenterology. 1999. PMID: 9869598 Clinical Trial.

4

Methotrexate in refractory Crohn's disease.

Vandeputte L, D'Haens G, Baert F, Rutgeerts P. Vandeputte L, et al. Inflamm Bowel Dis. 1999 Feb;5(1):11-5. doi: 10.1097/00054725-199902000-00002. Inflamm Bowel Dis. 1999. PMID: 10028444

5

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. D'haens G, et al. Gastroenterology. 1999 May;116(5):1029-34. doi: 10.1016/s0016-5085(99)70005-3. Gastroenterology. 1999. PMID: 10220494 Clinical Trial.

6

Acute lower gastrointestinal bleeding in Crohn's disease: characteristics of a unique series of 34 patients. Belgian IBD Research Group.

Belaiche J, Louis E, D'Haens G, Cabooter M, Naegels S, De Vos M, Fontaine F, Schurmans P, Baert F, De Reuck M, Fiasse R, Holvoet J, Schmit A, Van Outryve M. Belaiche J, et al. Am J Gastroenterol. 1999 Aug;94(8):2177-81. doi: 10.1111/j.1572-0241.1999.01291.x. Am J Gastroenterol. 1999. PMID: 10445546

7

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Rutgeerts P, et al. Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x. Gastroenterology. 1999. PMID: 10500056 Clinical Trial.

8

Infliximab (Remicade), a new biological treatment for Crohn's disease.

D'Haens GR. D'Haens GR. Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):519-20. Ital J Gastroenterol Hepatol. 1999. PMID: 10575573 Review.

9

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. Gasche C, et al. Inflamm Bowel Dis. 2000 Feb;6(1):8-15. doi: 10.1097/00054725-200002000-00002. Inflamm Bowel Dis. 2000. PMID: 10701144

10

Crohn's disease and intestinal endometriosis: an intriguing co-existence.

Craninx M, D'Haens G, Cokelaere K, Baert F, Penninckx F, D'Hoore A, Ectors N, Rutgeerts P, Geboes K. Craninx M, et al. Eur J Gastroenterol Hepatol. 2000 Feb;12(2):217-21. doi: 10.1097/00042737-200012020-00014. Eur J Gastroenterol Hepatol. 2000. PMID: 10741938

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

591 results

Search Page